Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours

• DOI: 10.1111/bju.14372
• Publication Date: 2018-05-04T03:30:56Z
• Authors: Jeremy Lewin; Laleh Soltan Ghoraie; Philippe L. Bedard; Robert J. Hamilton; Peter Chung; Malcolm Moore; Michael A.S. Jewett; Lynn Anson‐Cartwr...; Carl Virtanen; Neil Winegarden; Julie Tsao; Padraig Warde; Joan Sweet; Benjamin Haibe‐Kains; Aaron R. Hansen
• Keywords: HMGA2

To identify differentially expressed genes between relapsed and non-relapsed clinical stage I testicular germ cell tumours (TGCTs).We reviewed patients with non-seminoma seminoma from an institutional database (2000-2012) who were managed by active surveillance. Patients defined as being relapse-free after 2 3 years of surveillance, respectively. RNA extraction gene expression analysis was performed on archival primary tumour samples gene-set enrichment (GSEA) conducted in order to differentiating biological pathways.A total 57 (relapsed non-seminoma, n = 12; seminoma, =15; 15; 15) identified, a median (range) relapse time 5.6 (2.5-18.1) 19.3 (4.7-65.3) months the cohorts, A 1 039 identified that separated groups. In relapse, GSEA revealed pathways associated differentiation, such skeletal development (i.e. FGFR1, BMP4, GLI2, SPARC, COL2A1), tissue COL13A1) bone remodelling CARTPT, MGP). discriminative profile cases discovered when combining using 10- 30-probe signatures; however, this not observed cohorts individually.A discriminating signature for disease TGCT we able histology alone. Further validation is required determine if provides independent prognostic information standard pathological risk factors.